Hypertensive Crisis Agents Market
Number of pages: 100 | Report Format: PDF | Published date: June 06, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
CAGR |
5.07% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global hypersensitive crisis agents market is expected to register a revenue CAGR of 5.07% during the forecast period from 2023 to 2031.
Hypertensive Crisis Agents Market Fundamentals
A hypertensive crisis is a severe increase in blood pressure that requires immediate medical attention. It is typically defined as a systolic blood pressure (the top number) of 180 mm Hg or higher or a diastolic blood pressure (the bottom number) of 120 mm Hg or higher. In the management of a hypertensive crisis, the primary goal is to lower blood pressure safely and gradually, usually over a period of minutes to hours. Several medications can be used to achieve this goal. High blood pressure often develops gradually. It can occur due to bad lifestyle choices, such as not obtaining enough regular physical activity. Diabetes and obesity can also raise the chance of getting high blood pressure.
Hypertensive Crisis Agents Market Dynamics
Hypertension, or high blood pressure, is a common medical condition affecting a significant proportion of the global population. As the prevalence of hypertension continues to rise, hypertensive crises also increase, thereby driving the demand for hypertensive crisis agents. According to the 'World Heart Federation's 2021 report, hypertension affects about 1.3 billion individuals (one in every four adults) worldwide. Furthermore, the death rate from hypertension is roughly 16.94% in North America, 9.3% in Africa, and 25% in Russia. There is a growing emphasis on early diagnosis and management of hypertension to prevent complications such as hypertensive crises.
Additionally, increasing awareness among individuals and healthcare professionals about the importance of blood pressure control is driving the demand for hypertensive crisis agents. Pharmaceutical companies are investing in research and development activities to develop more effective and targeted hypertensive crisis agents. In addition, the novel formulations, drug combinations, and delivery methods are being explored to improve the efficacy and safety of these medications, thus driving the market growth. The development of advanced blood pressure monitoring devices has improved the detection and monitoring of hypertensive crises. Technological advancements, such as wearable blood pressure monitors and remote patient monitoring systems, enable timely intervention and management of hypertensive crises, further driving the demand for appropriate medications. Rising healthcare expenditure, particularly in developing economies, contributes to the hypertensive crisis agent’s market growth. Improved access to healthcare facilities and increased affordability of medications are driving the demand for hypertensive crisis agents. The global population is aging, leading to a higher prevalence of hypertension and related complications. The elderly population is more susceptible to hypertensive crises, which is creating a significant demand for appropriate medications and driving the market growth. For instance, the United States Census Bureau predicted that about 55,892,014 individuals in the United States were 65 and over in 2021, based on the American Community Survey, out of a total population of 331,893,745, or 16.8%.
Hypertensive crisis agents, especially those used in acute settings, can have potent effects on blood pressure. Using these medications carries the risk of adverse effects and complications, such as hypotension (low blood pressure), electrolyte imbalances, organ damage, and allergic reactions. Safety concerns associated with these agents may impact their adoption and usage. The development and approval of hypertensive crisis agents involves rigorous regulatory processes. Additionally, meeting the regulatory requirements for safety and efficacy, including conducting clinical trials, can be time-consuming and costly. These requirements can pose challenges for pharmaceutical companies in bringing new agents to the market. In some regions, there may be limited availability or accessibility to hypertensive crisis agents, particularly in low-resource settings. This can be due to factors such as inadequate healthcare infrastructure, lack of awareness, or economic constraints.
Moreover, limited availability and accessibility can hinder the effective management of hypertensive crises. Some patients may not respond adequately to hypertensive crisis agents, leading to treatment challenges. This can be due to individual variations in drug metabolism, genetic factors, underlying medical conditions, or interactions with other medications. In some cases, patients may develop resistance to certain agents over time, necessitating the use of alternative treatment strategies.
Hypertensive Crisis Agents Market Ecosystem
The global hypertensive crisis agents market has been analyzed from the following perspectives: by drug class, distribution channel, and region.
Hypertensive Crisis Agents Market by Drug Class
Based on the drug class, the global hypertensive crisis agents’ market is segmented into beta-blockers, vasodilator, calcium channel blockers, angiotensin-converting-enzyme inhibitors, alpha adrenergic antagonist, and others.
Beta- blockers account for significant revenue shares in the global market. Beta-blockers are one of the commonly used classes of medications in the management of hypertensive crises. Beta-blockers are used for hypertensive crises and have multiple indications, such as angina, heart failure, arrhythmias, and myocardial infarction. Due to their versatility and effectiveness in managing various cardiovascular conditions, beta-blockers are frequently prescribed and widely used by healthcare professionals. Many patients experiencing hypertensive crises also often have concurrent cardiovascular conditions such as coronary artery disease, heart failure, or arrhythmias. For instance, according to ‘American Heart Association,’ in 2020, nearly 19.1 million deaths were caused by cardiovascular diseases globally.
Furthermore, these beta-blockers have shown benefits in managing these comorbidities, making them a preferred choice in patients with hypertensive crises and associated cardiovascular conditions. Moreover, they are available in various generic forms, making them more accessible and affordable than newer, patented medications. The widespread availability and affordability of beta-blockers contribute to their dominance in the global hypertensive crisis agent’s market. Beta-blockers are generally well-tolerated, with a known safety profile. However, as with any medication, they can have potential side effects, such as bradycardia (slow heart rate), fatigue, and bronchospasm in patients with underlying respiratory conditions. Despite these potential side effects, beta-blockers are considered safe when used appropriately under medical supervision.
Hypertensive Crisis Agents Market by Distribution Channel
Based on the distribution channel, the global hypertensive crisis agents market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Hospital pharmacies dominate the global hypertensive crisis agents market with a largest revenue share. Hypertensive crises often require immediate medical attention and management in an acute care setting, such as hospitals or emergency departments. Hospital pharmacies are responsible for procuring and supplying the necessary medications for the management of hypertensive crises in these settings. They stock a wide range of hypertensive crisis agents to ensure their availability for timely administration. Hospital pharmacies work closely with healthcare professionals, including physicians, nurses, and pharmacists, in managing hypertensive crises. They collaborate in selecting the appropriate hypertensive crisis agents based on the patient's condition, medical history, and individual requirements. Hospital pharmacists also provide valuable input regarding medication dosages, compatibility, and potential interactions. Hospitals typically maintain a drug formulary, which is a list of medications approved for use in their facility. In severe hypertensive crises, intravenous administration of medications is often necessary to achieve rapid and precise blood pressure control. Hospital pharmacies are responsible for preparing intravenous formulations of hypertensive crisis agents, ensuring accurate compounding and appropriate dilution for safe and effective administration.
Hospital pharmacies often engage in collaborative drug therapy management, working closely with healthcare teams to optimize medication therapy. In the case of hypertensive crises, hospital pharmacists may provide recommendations for medication selection, dosing adjustments, and monitoring parameters. Their involvement helps to ensure appropriate and individualized management of hypertensive crises.
Hypertensive Crisis Agents Market by Region
Based on the region, the global hypertensive crisis agents market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America has a relatively high prevalence of hypertension, with a significant portion of the population affected by this condition. The higher incidence of hypertension leads to increased hypertensive crises, driving the demand for hypertensive crisis agents in the region. For instance, according to a CDC report, In the United States in 2021, hypertension was a major or contributing cause of 691,095 deaths. North America has a well-developed healthcare infrastructure, including hospitals, clinics, and emergency care facilities. This infrastructure supports timely diagnosis, treatment, and management of hypertensive crises. Well-equipped hospital pharmacies and emergency departments ensure the availability of a wide range of hypertensive crisis agents. The region is known for its advancements in medical technology, including blood pressure monitoring devices and other diagnostic tools. These technological advancements aid in early detection, monitoring, and management of hypertensive crises. Improved monitoring capabilities facilitate better control of blood pressure and enhance the effectiveness of hypertensive crisis agents. North America is home to some of the largest pharmaceutical companies globally, with a robust research and development sector. The region's pharmaceutical industry invests in the development and production of hypertensive crisis agents, ensuring a steady supply of these medications. The presence of innovative and generic pharmaceutical manufacturers contributes to the availability and market dominance of hypertensive crisis agents. North America has well-established healthcare policies and guidelines that emphasize the management of hypertension and hypertensive crises. Organizations like the American Heart Association (AHA) and the Canadian Hypertension Society provide evidence-based recommendations for the treatment and control of hypertension. These guidelines influence clinical practice and contribute to the market dominance of hypertensive crisis agents. North America has relatively higher healthcare spending compared to many other regions. This enables better access to healthcare services, including the management of hypertensive crises. Adequate healthcare funding and insurance coverage contribute to the region's affordability and availability of hypertensive crisis agents. Like many developed regions, North America has an aging population. Older adults are more susceptible to hypertension and hypertensive crises, leading to a higher demand for effective management strategies and hypertensive crisis agents.
Competitive Landscape
The prominent players operating in the global hypertensive crisis agents market are:
A hypertensive crisis is a severe increase in blood pressure that requires immediate medical attention.
Baxter Healthcare Corporation, Pfizer Inc., Novartis AG, and Nexus Pharmaceuticals Inc. are some of the major market players in the global hypertensive crisis agents market.
Side effects of these drugs and problems related to resistance and non-responsiveness are some of the restraints obstructing the growth of the global market.
The hospital pharmacies segment dominates the global hypertensive crisis agents market.
A growing aging population and a high prevalence of hypertension are some of the major factors driving the global market.
*Insights on financial performance are subject to the availability of information in the public domain